Press Release<< Back
Aptar Acquires Nanopharm and Gateway Analytical, Broadening Pharma Services Platform to Accelerate Customer Drug Development
Both acquisitions bring complementary, value-added and differentiated analytical, testing and development services for all stages of drug development and commercialization. The expanded services platform will enable Aptar Pharma to collaborate earlier with customers to support their complex drug formulations and delivery requirements as they face increasingly competitive and regulated markets.
Nanopharm, located in
“We are delighted to welcome the talented teams of Nanopharm and Gateway
and their customers to Aptar Pharma,” commented
Aptar is a leading global supplier of a broad range of innovative
dispensing, sealing and active packaging solutions for the beauty,
personal care, home care, prescription drug, consumer health care,
injectables, food and beverage markets. Aptar uses insights, design,
engineering and science to create innovative packaging technologies that
build brand value for its customers, and, in turn, make a meaningful
difference in the lives, looks, health and homes of people around the
world. Aptar is headquartered in
Nanopharm is a leading provider of tailored analytical and drug development services, with a focus on orally inhaled and nasal drug products. The company’s unique processing technologies and formulation development tools enable seamless translation of pre-clinical development through to clinical manufacturing. Nanopharm’s integrated development services in materials characterization, formulation development and inhaled biopharmaceutics aids successful product development by understanding how material properties and processing conditions influence product functionality. For more information, visit www.nanopharm.co.uk.
About Gateway Analytical
Gateway Analytical is the innovative analytical testing laboratory that businesses around the world trust to provide solutions for their most challenging foreign particulate analysis, foreign particulate identification and materials analysis needs. Gateway’s expert scientists, specialized testing techniques and comprehensive analysis methods allow the company to deliver the fast, accurate and reliable results that customers in the pharmaceutical, materials and medical device industries demand. To learn more about Gateway Analytical and how it is making the world healthier and safer, visit www.gatewayanalytical.com.
This press release contains forward-looking statements. Words such as
“future” and other similar expressions or future or conditional verbs
such as “will” are intended to identify such forward-looking statements.
Forward-looking statements are made pursuant to the safe harbor
provisions of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934 and are based on our beliefs as
well as assumptions made by and information currently available to us.
Accordingly, our actual results may differ materially from those
expressed or implied in such forward-looking statements due to known or
unknown risks and uncertainties that exist in our operations and
business environment including, but not limited to: the successful
integration of acquisitions; significant fluctuations in foreign
currency exchange rates; and competition, including technological
advances. For additional information on these and other risks and
uncertainties, please see our filings with the
Investor Relations Contact:
+1 815 477 0424
+33 1 39 17 20 38